Panel configurator
Request the FixVUE, FlexVUE and U-VUE panels you need.
Log in FlexVUE configurator U-VUE configurator FixVUE panels
Panel configurator
Request the FixVUE, FlexVUE and U-VUE panels you need.
Log in FlexVUE configurator U-VUE configurator FixVUE panels
Senior Field Application Scientist, Ultivue
Relevant for
InSituPlex
Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. The urgency to discover and implement new biomarkers lays bare the need to integrate a variety of advanced tools to probe the dynamic nature of events happening in the tumor microenvironment (TME). Recently, technology updates integrating the use of multiplex immunohistochemistry/immunofluorescence (mIHC/IF) provides much needed insight into cellular composition, cellular functions, and cell-cell interactions. Importantly, recent studies have used mIHC/IF to explore specific immune cells as part of the tumor immune microenvironment (TME) and found that it is helpful for clinical prognosis and efficacy prediction in patients with cancer. In this presentation we will show a streamlined unique workflow supporting whole slide imaging of an 8-plex mIF and traditional same slide H&E fusion on a single tissue slide for a comprehensive tissue immunophenotyping analysis.
Troy is an experienced analytical histotechnologist with expertise in histology, immunohistochemistry, in situ hybridization, digital slide scanning and image analysis within the GLP/GCP and pre-clinical environments along with a strong multidisciplinary CDx and research experience in models of oncology and autoimmune diseases.
Sr. Director Molecular & Computational Pathology, Ultivue
Relevant for
InSituPlex
Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.
As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.
I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.
Associate Director Scientific Affairs, Ultivue; Chief Science Officer, OracleBio
Relevant for
InSituPlex
Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.
As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.
I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.
Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.
Relevant for
Collaboration, FixVUE, InSituPlex
Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.
Director of R&D and Innovation, Ultivue
Relevant for
InSituPlex
Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.
As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.
I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.
Vice President, Medical Director, Ultivue
Relevant for
InSituPlex
Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.
As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.
I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.
Presented at: ASCO 2022
Relevant for
Collaboration, FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
Principal Pathologist-Scientist, Genentech
Relevant for
FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Presented at: ASCO 2022
Relevant for
FixVUE, InSituPlex, RNA scope
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
Presented at: ASCO 2022
Relevant for
FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
Presented at: ASCO 2022
Relevant for
FlexVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
Presented at: ASCO 2022
Relevant for
Collaboration, FixVUE, Imaging mass cytometry, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry
Senior Product Manager AI & Data Analytics
Relevant for
FixVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Senior Product Manager AI & Data Analytics
Relevant for
FlexVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Moritz will drill his way through whatever intellectual challenge you’ll put in front of him. He previously perforated biochemistry, image analysis, data science, immuno-oncology biomarkers, product management/ownership. He’ll condense the best of our ideas into a coherent roadmap. His product backlog will guide us towards our vision one step at a time.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Senior Director Scientific Brand Strategy
Relevant for
FlexVUE, InSituPlex
Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
